Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD
Bone Marrow Transplantation (https://doi.org/10.1038/s41409021-01529-x)
November 23, 2021
Results from an expanded access program of the anti-CD3/CD7 immunotoxin combination (T-Guard) for the treatment of steroid-refractory acute GVHD
ASH Annual Meeting 2019, Orlando
December 19, 2019
Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease
Biol Blood Marrow Transplant 25 (2019) 712-719
October 25, 2019
Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study
International Journal of Pharmaceutics 221 (2001) 175–186
March 30, 2001
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease
Blood • Volume 95, Number 12
June 15, 2000